Small molecule (PROTAC degrader) · Degrader of Signal transducer and activator of transcription 3 (STAT3) · developed by Kymera Therapeutics
Lirodegimod (KT-333) is a heterobifunctional small molecule that binds STAT3 and recruits an E3 ubiquitin ligase to it, leading to STAT3 ubiquitination and proteasomal degradation. It is being studied in non-Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, large granular lymphocytic leukemia, T-cell prolymphocytic leukemia and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05225584 | Phase 1 | Non Hodgkin Lymphoma (NHL) | Completed | KYMR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cutaneous T-Cell Lymphoma (CTCL)Large Granular Lymphocytic Leukemia (LGL-L)Non Hodgkin Lymphoma (NHL)Peripheral T-cell Lymphoma (PTCL)Solid TumorsT-cell Prolymphocytic Leukemia (T-PLL)
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.
See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYMR catalysts and pipeline →